VWR, the leading global independent provider of product and service solutions to laboratory and production facilities, will be the exclusive distributor for StemBioSys in both the United States and Canada. [Read more…]
First Ever Employer to Store Lifesaving Stem Cells for Employees
Edinburgh, UK, December 7, 2016 – Precious Cells is offering their employees the ultimate employee benefit unlike anything ever seen before. They will cryogenically store employees’ and their loved ones’ stem cells, for free. This means they can be used in treatment for life threatening conditions today, tomorrow and in the future. [Read more…]
Recently, Biological Industries (BI) submitted a Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for purposes of moving its NutriStem® hPSC XF Medium toward being certified for clinical applications. The product is a defined, xeno-free (XF), serum-free (SF) medium that supports the growth and expansion of human induced pluripotent stem (iPS) and embryonic stem cells (ESCs). [Read more…]
Kimera Labs, a specialty contract research organization (CRO), has announced the launch of a 6,000 sq ft, ISO:9001 certified exosome production facility in Miramar, Florida. As an FDA registered tissue facility, Kimera Labs Miramar will produce tissue specific mesenchymal stem cell (MSC) derived exosomes, as well as its Amnio2x amniotic fluid derived products. Amnio2x can be used for orthopedic, cosmetic and regenerative medicine applications.
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. Exosomes are commonly found in blood, urine, saliva, synovial fluid, amniotic fluid, semen, and many other fluids. [Read more…]
Singapore’s CellResearch Corporation has entered into an agreement with CariCord to provide umbilical cord tissue banking services within the United States. CariCord is the private cord blood and tissue banking partner of ClinImmune Labs at the University of Colorado.
As stated in the November 30, 2016, press release:
“CellResearch Corporation Pte Ltd (“CellResearch”), a Singapore-based company that specializes in stem cell technology, through its wholly owned subsidiary, CordLabs Pte Ltd (“CordLabs”), has entered into an agreement with CariCord Inc. (“CariCord”) to provide umbilical cord tissue banking services in the United States. CariCord is the private postnatal cord blood and tissue banking partner of ClinImmune Labs (“ClinImmune”) at the University of Colorado, Anschutz Medical Campus (“UCAMC”).
This agreement extends CellResearch’s on-going collaboration with ClinImmune. The two groups are already working together to obtain US Federal Drug Agency (“US FDA”) approval for Corlicyte™, a drug for the treatment of diabetic wounds. ClinImmune will produce the world’s first Current Good Manufacturing Practices (“cGMP”) cord lining mesenchymal stem cell lines for therapeutic use.”
This license agreement also allows CariCord’s cord tissue clients to join CellResearch’s Global Cord Registry (“GCR”), “a proprietary registry for all clients who have saved cord lining stem cells with licensed partners.” The registry currently has 50,000+ registered clients, making it the largest group of its type in the world.